As contrast market founders, radiopharmaceuticals show promise

04/30/2013 | DOTMed.com

The decline in the U.S. contrast agents market is likely to last until 2017, according to this article. Companies expected to be affected include GE Healthcare, Mallinckrodt and Lantheus Medical Imaging. However, analyst Ravindra Sharma said the radiopharmaceuticals sector is a promising area, and the CMS decision on Amyvid will be watched closely. Another trend in the field is advancement not just in the chemical composition of contrast agents but in how they are administered, such as in the use of software to allow for integration of injectors, PACS and imaging devices.

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC